Company / Current Liabilities
Janux Therapeutics, Inc. Current Liabilities History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$25.0M
FY2025
5-year range
$12.8M / $25.0M
FY2021-FY2025
Trend
+43.2%
vs FY2024
Sector context
#185 of 215
Health Care
What the data says
Janux Therapeutics, Inc.'s current liabilities of $25M is lower than 86% of companies in the Health Care sector (FY2025). Increased from $13M to $25M over the past 2 years.
Based on SEC 10-K filings.
$25M in FY2025 with a 5-year CAGR of +51.0%.
Increased from $13M to $25M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +14.8%
- 5-Year CAGR
- +51.0%
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 215This company $25.0M Sector average $1.6B
▼
-98.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +51.0%, indicating consistent growth.
- In FY2025, current liabilities increased 43.2% year-over-year.
- Ranks #185 out of 215 companies in the Health Care sector.
- Lowest current liabilities in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $25.0M | +43.2% |
| FY2024 | $17.5M | +34.0% |
| FY2023 | $13.0M | -21.0% |
| FY2022 | $16.5M | +29.0% |
| FY2021 | $12.8M | +302.3% |
| FY2020 | $3.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026